- Ackermans & van Haaren spearheaded the investment round, with participation from both new investors including Driehaus Capital Management and Quest for Growth. Current investors namely BioGeneration Ventures, Capricorn The post Confo...
- AbbVie Ventures led the investment round and, as part of its commitment, the company’s associate director Danjuma Quarless will join the board of directors of Oisín. As part The post Oisín secures funds to advance treatments for...
- The designation comes after the FDA reviewed the available initial clinical data showing AIC100’s potential to treat recurrent ATC. RMAT designation is aimed at expediting the development and The post FDA grants RMAT designation to...
- A subsidiary of Bayer, the company aims to enhance its chemoproteomics screening capacity and further its clinical and preclinical programmes with this new facility. The centre will also The post Vividion Therapeutics to expand...
- This alliance is aimed at transforming scientific breakthroughs at Oxford into potential new treatments. Under the deal, Apollo will detect and evaluate established therapeutic targets from Oxford’s biomedical The post Apollo...
- This designation aims to expedite the development and review of the therapy for paediatric patients with early-stage type 1 diabetes carrying the HLA DR3-DQ2 genotype. The status aids The post Diamyd Medical secures FDA fast track status...
- Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 AFFINE study (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gene therapy for the treatment of adults with moderately severe to...
- Data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) study, the first and largest clinical trial of pre-symptomatic Alzheimer's disease, is now widely available to researchers studying the condition. The comprehensive...
- Antibiotics are crucial in modern medicine, but their widespread use has led to antibiotic-resistant bacteria, posing a serious public health threat. A new study highlights the potential of random antimicrobial peptide mixtures to...
- Relapsed/refractory acute myeloid leukemia (AML), a so-called blood cancer, has an extremely poor prognosis because of resistance to anti-cancer drugs and frailty of the patient’s organ functions. A type of anti-tumor immunotherapy...
- Champion VC and LRM founder and CEO Dr Samuel Lynch spearheaded the financing round. This funding will support the company’s efforts to leverage its patented pure platelet-derived growth The post Lynch Regenerative Medicine secures funds...
- The new line, representing an investment of nearly €6.6m ($7.1m), is located at the Life Science Center in Nantong. This development is aimed at meeting the increasing local The post Merck launches GMP-compliant cell culture media line...
- SPS is a rare, debilitating neurological autoimmune disorder characterised by muscle stiffness and spasms. Kyverna’s KYV-101 is an autologous, fully human CD19 CAR T-cell therapy designed to address The post US FDA grants RMAT...
- The deal, which was announced in May 2024, includes an upfront cash payment of $1.3bn and $1.7bn in milestone payments on meeting developmental, regulatory and commercial goals. Under The post Merck enhances ophthalmology portfolio with...
- Peek inside the human genome and, among the 20,000 or so genes that serve as building blocks of life, you’ll also find flecks of DNA left behind by viruses that infected primate ancestors tens of millions of years ago. These ancient...
- The Phase III ARANOTE trial, investigating darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC), has met its primary endpoint of rPFS. Darolutamide plus ADT significantly increased rPFS compared to...
- Pfizer Inc. (NYSE: PFE) announced that based on results from the ongoing pharmacokinetic study (NCT06153758), the company has selected its preferred once-daily modified release formulation for danuglipron, an oral glucagon-like peptide-1...
- Proteins have evolved to excel at everything from contracting muscles to digesting food to recognizing viruses. To engineer better proteins, including antibodies, scientists often iteratively mutate the amino acids - the units that are...
- A method to screen a wide variety of drug candidates without laborious purification steps could advance the fight against drug-resistant bacteria. Efforts to combat the increasing threat of drug-resistant bacteria are being assisted by a...
- Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the United States (U.S.) Food and Drug Administration (FDA) has...
- Individuals diagnosed with prediabetes can reduce their long-term risk of death and diabetes-related health complications if they delay the onset of diabetes for just four years through diet and exercise. Guangwei Li of the China-Japan...
- Certain types of light have proven to be an effective, minimally invasive treatment for cancers located on or near the skin when combined with a light-activated drug. But deep-seated cancers, surrounded by tissue, blood and bone, have...
- A new approach to treating the most malignant type of brain cancer - glioblastoma - has shown strong promise in pre-clinical settings, raising hopes of increasing current average survival rates beyond 18 months. Targeted alpha therapy...
- A new study led by investigators from Mass Eye and Ear found that patients prescribed semaglutide (as Ozempic or Wegovy) for diabetes or weight loss had a higher risk of having a potentially blinding eye condition called NAION than...
- Twelve years ago, cancer researchers at University of California San Diego identified a molecule that helps cancer cells survive by shuttling damaging inflammatory cells into tumor tissue. In new research, they show that the same...
- GSK plc (LSE/NYSE: GSK) and CureVac N.V. (Nasdaq: CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritise investment and focus their respective mRNA...
- New UCSF study shows that suppressing a protein turns ordinary fat into a calorie burner and may explain why drug trials attempting the feat haven’t been successful. Researchers at UC San Francisco have figured out how to turn ordinary...
- AstraZeneca's Marketing Authorisation Application (MAA) for sipavibart has been accepted under an accelerated assessment procedure by the European Medicines Agency (EMA), for the pre-exposure prophylaxis (prevention) of COVID-19 in...
- When a cancer cell doesn't respond to traditional therapies, doctors may turn to a sort of viral biological warfare, by deploying 'troops' in the form of viral agents that are specifically engineered to target and eliminate cancer cells....
- Antibiotic-resistant bacterial infections are becoming a major societal challenge. To solve this problem, researchers are working on new drugs that kill bacteria without developing resistance, and on new materials that prevent the...
- The inflammatory disease affects around one in 2,000 people in the US
- Results from a mid-stage of the candidate were recently published in the NEJM
- The skin disease affects an estimated 1% of the population in most studied countries
- The collaboration will first focus on developing products for long COVID and ME/CFS
- Researchers used a technique to identify specific molecular details of biotin-labelled proteins
- Around 60,000 people are diagnosed with pancreatic adenocarcinoma in the US every year
- The company gained access to the drug through its $7.3bn acquisition of Reata Pharmaceuticals
- The drug could prevent conditions including diabetic eye and kidney disease in diabetes
- The Yellow Card Biobank will begin investigating direct oral anticoagulants such as apixaban
- The deal gives the company access to a candidate being evaluated in primary biliary cholangitis
- There are now more than 8,000 patients who are potentially eligible for treatment with Casgevy
- Approximately one in 10,000 people are affected by the genetic blood clotting disorder
- The rare genetic disorder is estimated to affect around one in every 40,000 people in the UK
- F404 mutations combined with pre-existing mutations caused resistance to fulvestrant
- Both companies will leverage their autologous CAR-T cell therapy programmes
- Ten23 health expands former swissfillon facility in Visp, Switzerland jkeenan Mon, 03/28/2022 - 08:41
- Sobi to trim staff as Pfizer manufacturing contract ends early jkeenan Thu, 03/24/2022 - 08:40
- Epinephrine recall: Adamis pulls Symjepi injections for needle clogging risks aliu Wed, 03/23/2022 - 11:18
- Fujifilm makes yet another deal to jack up cell and gene therapy capacity kdunleavy Tue, 03/22/2022 - 21:13
- Takeda's Natpara relaunch bid falls flat as manufacturing concerns drag on jkeenan Tue, 03/22/2022 - 09:22